Is Peregrine Preparing to Soar Again?

In this video, health-care analyst David Williamson discusses Peregrine Pharmaceuticals' announcement and stock pop from completing enrollment of a phase 1 trial for its lead drug candidate bavituximab in breast cancer. Bavituximab has endured a lot of (clinical) trials and tribulations, including in NSCLC and pancreatic cancer, and this video puts today's news into perspective with the larger picture investors need to know.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today simply click here now.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 02, 2013, at 3:10 PM, BSDetector wrote:

    I chose this video thinking that I would learn more about PPHM. Silly me. Only midway through did I learn that I was watching a Celgene commercial.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2395541, ~/Articles/ArticleHandler.aspx, 10/31/2014 2:22:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement